KF31327 is a potent non-benzodiazepine GABA-A receptor partial agonist belonging to the imidazoquinazoline class, developed to treat anxiety disorders and insomnia by modulating central nervous system… Read more
KF31327 is a potent non-benzodiazepine GABA-A receptor partial agonist belonging to the imidazoquinazoline class, developed to treat anxiety disorders and insomnia by modulating central nervous system activity. Pharmaceutical laboratories utilize this category of compounds, including related impurities, metabolic degradation products, and stable isotope-labelled standards, to ensure rigorous quality control and accurate analytical assessment. These reference standards are critical for impurity profiling and the precise quantification of trace contaminants in drug substance batches. Furthermore, stable isotope-labelled versions are essential for bioanalytical method validation and high-resolution mass spectrometry applications, allowing researchers to track metabolic pathways and pharmacokinetics with high sensitivity. By providing consistent, high-quality analytical markers, these compounds facilitate compliance with regulatory standards throughout the drug development lifecycle, ensuring both efficacy and safety in clinical applications.